<DOC>
	<DOCNO>NCT01724021</DOCNO>
	<brief_summary>This multi-center , open-label , randomize study evaluate participant preference subcutaneous versus intravenous administration MabThera/Rituxan ( rituximab ) participant CD20+ diffuse large B-cell lymphoma CD20+ follicular non-Hodgkin 's lymphoma . In Arm A , participant receive MabThera/Rituxan 375 mg/m2 intravenously ( IV ) Day 1 Cycle 1 MabThera/Rituxan 1400 mg subcutaneously ( SC ) Day 1 Cycles 2-4 , follow MabThera/Rituxan IV Cycles 5-8 . Participants Arm B receive MabThera/Rituxan IV Cycles 1-4 SC Cycles 5-8 . All participant receive 6-8 cycle standard chemotherapy ( accord local country practice ) 8 cycle MabThera/Rituxan . Anticipated time study treatment 24 week .</brief_summary>
	<brief_title>A Study Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan Participants With CD20+ Diffuse Large B-Cell Lymphoma CD20+ Follicular Non-Hodgkin 's Lymphoma Grades 1 , 2 3a</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Adult participant , &gt; /= 18 &lt; /= 80 year age Histologically confirm , previously untreated CD20+ diffuse large Bcell lymphoma ( DLBCL ) CD20+ follicular nonHodgkin 's lymphoma ( NHL ) Grade 1 , 2 , 3a , accord World Health Organization ( WHO ) classification An International Prognostic Index ( IPI ) score 14 IPI score 0 bulky disease , define one lesion &gt; /= 7.5 cm , Follicular Lymphoma International Prognostic Index ( FLIPI ; low , intermediate high risk ) At least one bidimensionally measurable lesion define &gt; /=1.5 cm large dimension CT scan Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 3 Transformed lymphoma follicular lymphoma IIIB Primary central nervous system ( CNS ) lymphoma , histologic evidence transformation Burkitt lymphoma , primary mediastinal DLBCL , primary effusion lymphoma , primary cutaneous DLBCL , primary DLBCL testis History malignancy could affect compliance protocol interpretation result ; include malignancy treat curative intent , unless malignancy remission &gt; /= 5 year prior enrolment ; participant history curatively treat basal squamous cell carcinoma melanoma skin situ carcinoma cervix eligible Prior therapy DLBCL NHL , exception nodal biopsy local irradiation Prior treatment cytotoxic drug ( exclusion intrathecal methotrexate CNS prophylaxis DLBCL ) rituximab another condition , prior use antiCD20 drug Prior use monoclonal antibody within 3 month prior randomization Chemotherapy investigational therapy within 28 day prior randomization Ongoing corticosteroid use &gt; 30 mg/day prednisolone equivalent Inadequate renal . hematologic hepatic function Active and/or severe infection major episode infection within 4 week prior randomization Active hepatitis B virus active hepatitis C virus infection History human immunodeficiency ( HIV ) seropositive status A positive pregnancy test woman childbearing potential Life expectancy le 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>